Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Genentech | Vismodegib | Erivedge | 2025-09-02 | 2012-01-30 |  |  |
Horizon Therapeutics Public | Interferon gamma-1b | Actimmune |  | 1999-02-25 | $122.816 M | Q3/22-Q2/23 |
Merck Sharp & Dohme | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
Organon | Alendronate, Cholecalciferol | Fosamax D |  | 2005-04-07 |  |  |
Roche | Vismodegib | Erivedge |  | 2013-07-12 | $303.263 M | Q4/22-Q3/23 |
Sandoz | Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol | Infuvite |  | 2000-05-18 |  |  |
Sun Pharmaceutical Industries | Sonidegib | Odomzo | 2029-07-24 | 2015-07-24 |  |  |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|